Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Orion Office REIT Inc — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.8 (market cap $6.04B), while Orion Office REIT Inc trades at $2.19 (market cap $125.50M). The key difference: Iovance Biotherapeutics Inc. Common Stock is far larger — about 48.1× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 3.64% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Orion Office REIT Inc for 33 Days on average.
| IOVA | ONL | |
|---|---|---|
Market Cap | $6.04B | $125.50M |
Volume | 14,805,993 | 303,276 |
Sector | Health | Real Estate |
52-Week High | $14.82 | $3.00 |
52-Week Low | $1.81 | $1.93 |
Typical Hold Time | 0 Days | 33 Days |
Enterprise Value | $5.97B | $542.43M |
Dividend Yield | — | 3.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ONL trades at $2.19, down 3.52% today, with a bearish technical signal despite a recent earnings beat. The REIT shows declining revenue from $208M in 2022 to $148M in 2025, with persistent net losses widening to -$139M. Positive cash flow of $3.47M in 2025 and a low P/B of 0.2 offer value, but high debt and negative margins pose challenges. Analysts are split 50/50 between Buy and Hold.
Outlook remains cautious; deep discount to book value and strategic portfolio repositioning may attract value investors, but sustained losses and office sector headwinds limit near-term upside. Key risks include leverage pressure and execution of turnaround plans amid weak demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
